Takeda Layoffs

Takeda Pharmaceutical says it is going to cut more than 1,400 jobs from its U.S. operations as it preps for generic competition to diabetes blockbuster Actos, Chicago Breaking Business reports.

Recent News and Discussions About Takeda Layoffs

Takeda plans layoffs in R&D reorganization – ACS Publications

https://pubs.acs.org/doi/10.1021/cen-09432-buscon010

Takeda plans layoffs in R&D reorganization - ACS Publications
Takeda Pharmaceutical will eliminate an unspecified number of jobs as part of an R&D revamp. The company says it plans to centralize research in the U.S. …


Layoff surge hits 3 more biotech companies

https://www.fiercebiotech.com/biotech/layoff-surge-hits-4-more-biotech-companies

Mar 31, 2022 — With more than 30 layoffs tallied by Fierce Biotech, the overpopulated industry is being forced to cut down. Today, immuno-oncology biotech …


Takeda Pharmaceuticals – Recent Layoffs Crippled Company

https://www.glassdoor.com/Reviews/Employee-Review-Takeda-Pharmaceuticals-RVW14710562.htm

Layoffs disposed of long time company employees with great track records in favor of cheaper new … Discover more reviews about Takeda Pharmaceuticals.


Global News Releases – Takeda

https://www.takeda.com/newsroom/newsreleases/

A searchable database of news releases from Takeda .


Takeda Layoffs – TheLayoff.com

https://www.thelayoff.com/takeda

About Takeda : Takeda Pharmaceutical Company Ltd (AKA Takeda Pharmaceuticals) is a large Japanese pharmaceutical company. It employs over 30,000 people worldwide …


Layoffs at Takeda | Science | AAAS

https://www.science.org/content/blog-post/layoffs-takeda

Aug 1, 2016 — Unfortunately, I have another round of layoffs and cutbacks to announce. Takeda has been talking about rearranging its R&D for months now, …


Takeda Plans 2800 Job Cuts – Manufacturing.net

https://www.manufacturing.net/home/news/13198058/takeda-plans-2800-job-cuts

Takeda says it will cut 2,100 jobs in Europe and 700 in the U.S., and it also plans to combine or eliminate some subsidiaries, mostly in Europe. The cuts will …


Takeda Pharmaceutical to cut sales jobs in Japan, sources say

https://www.reuters.com/article/us-takeda-jobs/takeda-pharmaceutical-to-cut-sales-jobs-in-japan-sources-say-idUSKCN24U0AW

Jul 28, 2020 — The layoffs by Takeda , Japan’s biggest drug maker, will be focused on sales positions, two industry sources told Reuters requesting …


Takeda | Cafepharma Message Boards

http://www.cafepharma.com/boards/forums/takeda.67/

Regeneron, Sanofi look to extend Dupixent into young kids with eosinophilic esophagitis —FDA infinitely delays BeiGene/Novartis esophageal cancer drug — FDA …


Ariad employees face mass layoffs after Takeda acquisition

https://www.bizjournals.com/boston/news/2017/03/30/ariad-employees-face-mass-layoffs-after-takeda.html

Mar 30, 2017 — Takeda , which bought Ariad for $5.2 billion in January, has found matching roles for fewer than half of the Cambridge biotech’s …


Frequently Asked Questions

Is Takeda a good company to work for?

94% of employees would recommend working at Takeda Pharmaceutical with the overall rating of 4.1 out of 5. Employees also rated Takeda Pharmaceutical 3.9 out of 5 for Company Culture, 4.3 for Rewards You Receive, 3.5 for Growth Opportunities and 4.3 for support you get.

Is Takeda moving to Boston?

As Takeda works to close its massive Shire buy, the company has unveiled a plan to close its Chicago-area U.S. headquarters and center its U.S. operations in the Boston area where Shire has operations. The move will affect 1,000 employees.

Is Takeda a Chinese company?

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet.

Is Takeda Pharmaceutical a buy?

3 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Takeda Pharmaceutical in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should “hold” Takeda Pharmaceutical stock.

Leave a Comment